- Conditions
- Lymphoproliferative Disorder
- Interventions
- rituximab, cyclophosphamide, methylprednisolone, prednisone
- Biological · Drug
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 30 Years
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2013
- U.S. locations
- 66
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 58 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 529–552
of 729
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Fractures, Bone, Fractures, Closed, Radius Fracture Distal
- Interventions
- Dexamethasone, Methylprednisolone, Standard of Care
- Drug · Other
- Lead sponsor
- Indiana Hand to Shoulder Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Metastatic Cancer, Neoplasm, Prostate, Castrate-sensitive, Castrate-sensitive Prostate Cancer
- Interventions
- Abiraterone acetate, Apalutamide, Enzalutamide
- Drug
- Lead sponsor
- Sun Pharmaceutical Industries Limited
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 192 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Tampa, Florida • Ann Arbor, Michigan + 9 more
- Conditions
- Cataracts, Corneal Edema, Retinal Structural Change, Deposit and Degeneration, Visual Acuity Reduced Transiently
- Interventions
- Difluprednate ophthalmic emulsion 0.05%, Prednisolone acetate 1%
- Drug
- Lead sponsor
- Edward J. Holland
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 3
- States / cities
- Edgewood, Kentucky • Lynbrook, New York • Mt. Pleasant, South Carolina
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With T(15;17)(q22;q12), Adult Acute Myeloid Leukemia With T(16;16)(p13;q22), Adult Acute Myeloid Leukemia With T(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Acute Promyelocytic Leukemia (M3), Adult Erythroleukemia (M6a), Adult Nasal Type Extranodal NK/T-cell Lymphoma, Adult Pure Erythroid Leukemia (M6b), Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Burkitt Lymphoma, Childhood Acute Erythroleukemia (M6), Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Megakaryocytic Leukemia (M7), Childhood Acute Monoblastic Leukemia (M5a), Childhood Acute Monocytic Leukemia (M5b), Childhood Acute Myeloblastic Leukemia With Maturation (M2), Childhood Acute Myeloblastic Leukemia Without Maturation (M1), Childhood Acute Myeloid Leukemia in Remission, Childhood Acute Myelomonocytic Leukemia (M4), Childhood Acute Promyelocytic Leukemia (M3), Childhood Chronic Myelogenous Leukemia, Childhood Myelodysplastic Syndromes, Chronic Phase Chronic Myelogenous Leukemia, Cutaneous B-cell Non-Hodgkin Lymphoma, De Novo Myelodysplastic Syndromes, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Hepatosplenic T-cell Lymphoma, Intraocular Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Peripheral T-Cell Lymphoma, Post-transplant Lymphoproliferative Disorder, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult Non-Hodgkin Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Refractory Multiple Myeloma, Relapsing Chronic Myelogenous Leukemia, Secondary Myelodysplastic Syndromes, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, Testicular Lymphoma, Waldenstrom Macroglobulinemia
- Interventions
- busulfan, cyclophosphamide, allogeneic bone marrow transplantation, methylprednisolone, methotrexate, cyclosporine
- Drug · Procedure
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1988 – 2010
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Heart Transplant
- Interventions
- tocilizumab, Placebo, Standard of Care Triple IS
- Biological · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 385 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 20
- States / cities
- Beverly Hills, California • La Jolla, California • Stanford, California + 15 more
- Conditions
- Colitis, Ulcerative
- Interventions
- Placebo, COLAL-PRED
- Drug
- Lead sponsor
- Prometheus Laboratories
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 190 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 89
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Montgomery, Alabama + 78 more
- Conditions
- Total Knee Arthroplasty
- Interventions
- Methylprednisolone, Placebo
- Drug
- Lead sponsor
- Rush University Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- Olaparib, Placebo, Abiraterone, Prednisone or prednisolone
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years · Male only
- Enrollment
- 158 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2023
- U.S. locations
- 2
- States / cities
- San Diego, California • Lake Success, New York
- Conditions
- Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis
- Interventions
- Ocrelizumab IV, Ocrelizumab SC, Methylprednisolone IV, Diphenhydramine IV, Dexamethasone given orally, Desloratadine given orally
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 236 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 7
- States / cities
- Maitland, Florida • Tampa, Florida • Baltimore, Maryland + 4 more
- Conditions
- Devic's Disease
- Interventions
- Hematopoietic Stem Cell Transplantation, Cyclophosphamide, G-CSF, rATG, Mesna, Rituximab, Methylprednisolone
- Procedure · Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 16 Years to 65 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2018
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Healthy Subjects, Pharmacokinetics of Isavuconazole, Pharmacokinetics of Prednisolone
- Interventions
- Isavuconazole, Prednisone
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- Glendale, California
- Conditions
- Status Asthmaticus
- Interventions
- Montelukast Oral Granules, Albuterol, Corticosteroid
- Drug
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 4 Years to 12 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Lysosomal Diseases, Gangliosidosis, GM1
- Interventions
- AAV9-GLB1, Abdominal ultrasound, Rituximab, Sirolimus, Methylprednisolone, Prednisone, Audiology assessment with ABR, Bone density scan (DEXA), Electrocardiogram (EKG), Echocardiogram, Electroencephalogram (EEG) awake and extended overnight, Laboratory tests, Lumbar puncture, Brain MRI/MRS/fMRI, Neurocognitive testing, Neurology exam, PICC or other Central line placement, Skeletal survey, Skin biopsy, Speech and modified barium swallow study, Ophthalmology exam
- Biological · Procedure · Drug + 3 more
- Lead sponsor
- National Human Genome Research Institute (NHGRI)
- NIH
- Eligibility
- 6 Months to 12 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2030
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Post Cataract Surgery
- Interventions
- Triamcinolone (Optional), control group
- Drug
- Lead sponsor
- Research Insight LLC
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Laguna Hills, California
- Conditions
- Melanoma Stage III, Melanoma Stage IV, Skin Cancer Stage III, Skin Cancer Stage IV, Drug-Induced Colitis, Drug Toxicity, Immune-related Adverse Event
- Interventions
- Infliximab, Methylprednisolone, Prednisone
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2030
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- DRESS Syndrome, Drug-Induced Hypersensitivity Syndrome
- Interventions
- Cyclosporine, Methylprednisolone and Prednisone
- Drug
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Prostate Neoplasms
- Interventions
- Abiraterone acetate, Glucocorticoid
- Drug
- Lead sponsor
- Cougar Biotechnology, Inc.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 2
- States / cities
- San Francisco, California • New York, New York
- Conditions
- Alcoholic Hepatitis (AH)
- Interventions
- Selonsertib, Prednisolone, Placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 104 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 11
- States / cities
- Little Rock, Arkansas • Coronado, California • Los Angeles, California + 8 more
- Conditions
- Immune Reconstitution Inflammatory Syndrome, Leukoencephalopathy, Progressive Multifocal
- Interventions
- Methylprednisolone, Prednisolone
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Hastings, Nebraska
- Conditions
- Burkitt Lymphoma, High-grade B-cell Lymphoma, T-cell/Histocyte-rich Large B-cell Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Germinal Center B-cell Type (GCB)
- Interventions
- Rituximab, Etoposide, Copanlisib, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, ECHO, EKG, MRI Brain, 18F-FDG - PET, CT Scan, Bone Marrow Aspiration, Bone Marrow Biopsy, Lumbar Puncture (LP)
- Biological · Drug · Diagnostic Test + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Lung Transplant Rejection, Antibody-mediated Rejection
- Interventions
- Belatacept, Tacrolimus, ATG, Mycophenolate Mofetil, Methylprednisolone, Prednisone
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 2
- States / cities
- St Louis, Missouri • Houston, Texas
- Conditions
- Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Adult L1 Acute Lymphoblastic Leukemia, Adult L2 Acute Lymphoblastic Leukemia, Adult T Acute Lymphoblastic Leukemia, Recurrent Adult Acute Lymphoblastic Leukemia
- Interventions
- Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Cytarabine, Dasatinib, Dexamethasone, Doxorubicin Hydrochloride, Etoposide, Filgrastim, Laboratory Biomarker Analysis, Leucovorin Calcium, Methotrexate, Methylprednisolone, Peripheral Blood Stem Cell Transplantation, Prednisone, Sirolimus, Tacrolimus, Total-Body Irradiation, Vincristine Sulfate
- Procedure · Drug · Biological + 2 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 97 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2027
- U.S. locations
- 157
- States / cities
- Tucson, Arizona • Duarte, California • Palo Alto, California + 114 more
- Conditions
- Nephrotic Syndrome, Systemic Lupus Erythematosus
- Interventions
- prednisone, cyclophosphamide, cyclosporin A
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- Not listed
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1986 – 2004
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland